Search Within
Document Type
215-125-8
Applied Filters:
Keyword:'215-125-8'
Showing 1-30 of 101 results for "215-125-8" within Technical Documents
Data Sheet - F113
Pharmacol. 179, 211-215 (1990).
8. Kalia, M. "Reversible, short-lasting, and dose-dependent effect of (+)-fenfluramine on neocortical serotonergic axons." Brain
Res. 548, 111-125 (1991).
CONTROLLED
Mid-Infrared-based quantitation of highly modified proteins, labeled peptides and peptidomimetics
’s real MW
per amide (215) and divide by the BSA MW per amide (108).
Re-calculation examples:
BSA-based reading Recalculation Correct concentration
0.500 mg/mL 0.5 * (215/108) = 0.995 mg/mL
1.000
Poster- Solubility enhancement via amorphous solid dispersions
PBS 7.4 215
Parteck® MXP 4-88
Media pH Solubility at 37 °C (mg/mL)
SGF_sp 2 199.2
0.1M HCI 1 51.55
Acetate buffer 4.5 257.6
FaSSIF 6.5 55.25
PBS 6.8 54.8
PBS 7.4
Data Sheet - SAB4200121
. Acta, 1546,
205-215 (2001).
6. Piljic, A., and Schultz, C., Mol. Biol. Cell, 17,
3318-3328 (2006).
7. Kaetzel, M.A., et al., J. Biol. Chem., 269, 5297-
5302 (1994).
8. Kim, A., et al., Int.
User Guide (IFU) -1.00961
Measuring range and number of determinations
Measuring range 1) Number of determinations
5 - 215 mg/l Ca
0.9 - 37.6 °e 25
LABORATORY NOTEBOOK ISSUANCE PAGE
1 11 150 0.18 87 0.25
2 8 240 0.19 97 0.29
3 6 325 0.39 185 0.40
4 20–25 37 0.21 92 0.22
5 2.5 1,420 0.20 100 0.40
6 3 715 0.18 100
LABORATORY NOTEBOOK ISSUANCE PAGE
1 11 150 0.18 87 0.25
2 8 240 0.19 97 0.29
3 6 325 0.39 185 0.40
4 20–25 37 0.21 92 0.22
5 2.5 1,420 0.20 100 0.40
6 3 715 0.18 100
LABORATORY NOTEBOOK ISSUANCE PAGE
1 11 150 0.18 87 0.25
2 8 240 0.19 97 0.29
3 6 325 0.39 185 0.40
4 20–25 37 0.21 92 0.22
5 2.5 1,420 0.20 100 0.40
6 3 715 0.18 100
MAK394 - Technical Bulletin
25 L 0
2 2 L 223 L 25 L 20
3 4 L 221 L 25 L 40
4 6 L 219 L 25 L 60
5 8 L 217 L 25 L 80
6 10 L 215 L
Product Information Sheet-endoargs-ro
minutes linearly 0 to 100% B
Flow rate 1 ml/minute
Wavelength 215 nm
Fragments 4.49 min Asp (15) – Gln (20)
8.89 min His (1) – Ser (8)
13.78 min Asp (9) – Leu (14)
22.73 min Asp (21) – Thr
Product Information Sheet - 11370529001
; 70% acetonitrile (v/v)
Gradient 40 minutes linearly 0 to 100% B
Flow rate 1 ml/minute
Wavelength 215 nm
Fragments 15.95 min Gly (23) – Ala (30)
19.52 min Phe (1) – Arg (22)
https://www.sigmaaldrich.com
Data Sheet - A7952
(Ca2+-ATPase, 138 kDa) in immunoblotting.2-12 It may
recognize additional bands at approx. 215, 160-180,
125, 95-107, 72 and 27 kDa, that may represent
aggregation or proteolysis (dimers or combination
Product Information Sheet - T7409
7. USP, Vol. 23, p. 1611.
8. Wang, S.-S., and Carpenter, F.H., Kinetics of the
tryptic hydrolysis of the oxidized B chain of bovine
insulin. Biochemistry, 6(1), 215-224 (1967).
9. Proteolytic
Product Information Sheet - T0303
7. USP, Vol. 23, p. 1611.
8. Wang, S.-S., and Carpenter, F.H., Kinetics of the
tryptic hydrolysis of the oxidized B chain of bovine
insulin. Biochemistry, 6(1), 215-224 (1967).
9. Proteolytic
Glucagon Radioimmunoassay (RIA) Kit
25 - -
2 20 44 45 98%
3 50 73 75 97%
XP725 Antibody Number-Lot Number 071M4826
256 277 278 279 280
3.5 209 210 211 212 233 234 235 236 257 258 259 260 281 282 283 284
3.6 213 214 215 216 237 238 239 240 261 262 263 264 285 286 287 288
4.1 289 290 291
Understanding the Effect of Discreet PEG Linkers on ADC Structure and Binding
74 572 82 361 110
PEG24 4.0 257 66 612 77 293 135
LC-SMCC 2.7 154 109 374 125 288 138
PEG8 2.6 192 88 474 99 333 119
PEG24 2.8 215 79 555 84 272 146
Relative KD to the unmodified SigmaMAb
TB397VM pET-46 Ek/LIC Vector Map
4869
AvaI 1 5020
AvrII 1 5099
BanI 8 201 603 3355 3485 4204
4667 4781 4802
BanII 4 171 3921 4734 4748
BbeI 4 3489 4671 4785 4806
BbsI 3 3142 3639 3978
BceAI 5 215 1760 3640 4267 4607
BcgI 3 1194 2689
Product Information Sheet - C0926
News and Perspectives, 2(7), 410 (1989).
8. Cyclodextrin Technology, Szejtli, J., Kluwer
Academic Publishers (Dordrecht-Boston-London:
1988), pp. 211-215.
9. Rekharsky, M. K., et al., Complexation
20S Proteasome Activity Assay Kit
6. Hochstrasser, M. (1995), Curr. Opin. Cell Biol. 7: 215-223.
7. Meng, L, et al. (1999), Proc. Natl. Acad. Sci. USA 96: 10403-10408.
8. Fenteany, G and Schreiber, S. (1998), J. Biol. Chem. 273
Examination of Non-Specifically Bound Proteins and Peptides Following Depletion of Twenty High Abundance Proteins from Human Plasma
Disheveled-associated activator of morphogenesis 46 1
IPI00478493 HP protein 273 8 168 5 374 8
IPI00430808 Hypothetical protein 179 3 217 3 2071 3 215 2 207 3 257 3 483 5
IPI00399007 Hypothetical protein DKFZp 250
Eshmuno®CPS resin
buffer A
(total protein concentration 43.0 mg/mL)
• Load: 5 mL sample volume corresponding
to 215 mg total protein
• Column: 16 mm i.d. x 100 mm
• Column volume: 20.1 mL
• Residence time:
Product Information Sheet - MTOX1002
2010
White Paper), Membrane transporters in drug
development. Nature Reviews Drug Discovery, 9,
215-236 (2010).
2. Fleming, D.O. et al., (1995) Laboratory Safety:
Principles and Practice. Second
Product Information Sheet - MTOX1003
2010
White Paper), Membrane transporters in drug
development. Nature Reviews Drug Discovery, 9,
215-236 (2010).
2. Fleming, D.O. et al., (1995) Laboratory Safety:
Principles and Practice. Second
Product Information Sheet - MTOX1001
2010
White Paper), Membrane transporters in drug
development. Nature Reviews Drug Discovery, 9,
215-236 (2010).
2. Fleming, D.O. et al., (1995) Laboratory Safety:
Principles and Practice. Second
Programming data for Spectrophotometer and Spectroquant Test Kits
1.144 215 538 301 30.1 37.6 53.8
Absorbance
(A)
10-mm
Cell
mg/l Ca mg/l CaCO3 mg/l CaO °d °e °f
0.051 0 0 0 0 0 0
0.063 5 13 7 0.7 0.9 1.3
0.113 25
Product Information Sheet - MTOX1005
2010
White Paper), Membrane transporters in drug
development. Nature Reviews Drug Discovery, 9,
215-236 (2010).
2. Fleming, D.O. et al., (1995) Laboratory Safety:
Principles and Practice. Second
Product Information Sheet - MTOX1006
2010
White Paper), Membrane transporters in drug
development. Nature Reviews Drug Discovery, 9,
215-236 (2010).
2. Fleming, D.O. et al., (1995) Laboratory Safety:
Principles and Practice. Second
Product Information Sheet - MTOX1004
2010
White Paper), Membrane transporters in drug
development. Nature Reviews Drug Discovery, 9,
215-236 (2010).
2. Fleming, D.O. et al., (1995) Laboratory Safety:
Principles and Practice. Second
The Effective Use of Protein Kinase Inhibitors
actually
more potent in cell-based assays than they are in vitro.
For example, PD 98059 (Product Code P-215) and U0126
(Product Code U-120), which are non-competitive inhibitors
of mitogen-activated protein
Page 1 of 4